Explore our strategy and projects
to learn about the future of our company
Results FY 2024 (€/MLN)
1,185
Revenues
394
Adjusted EBITDA
236
Adjusted net profit
241
Free cash flow
Stock price
Discover morePress releases
20/03/26 - 17:44
Price sensitiveRevenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024
19/03/26 - 9:47
Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments